Wednesday, March 01, 2023 Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171) Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H. Coschi, Federica Grosso, Marie Florescu, Manlio Mencoboni, John R. Goffin, Maria Pagano, Fortunato Ciardiello, Fabiana Letizia Cecere, Mark Vincent, Roberto Ferrara, David E. Dawe, Desiree Hao, Christopher W. Lee, Alessandro Morabito, Cesare Gridelli, Luigi Cavanna, Mussawar Iqbal, Normand Blais, Natasha B. Leighl, Paul Wheatley-Price, Ming-Sound Tsao, Francesca Ugo, Hazem El-Osta, Piera Gargiulo, Pierre-Olivier Gaudreau, Dongsheng Tu, Joana Sederias,Pamela Brown-Walker,Francesco Perrone, Lesley Seymour, Scott A. Laurie Journal of Thoracic Oncology: https://www.jto.org/article/S1556-0864(23)00128-4/fulltext The purpose of this study was to find out what effects a new drug, pembrolizumab has on this type of cancer and if it can offer better results than standard pemetrexed and platinum-based chemotherapy alone. This study will also look at side effects and how the treatments impact quality of life.
